News Conference News ACC 2023 How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA Todd Neale March 09, 2023
News Features Heart Failure Care Has a Pipeline Problem: What’s the Fix? Shelley Wood December 20, 2022
News Daily News COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review Todd Neale October 12, 2022
News Daily News AHA Urges More Home-Based Dialysis in Advanced Kidney Failure Michael O'Riordan August 18, 2022
News Conference News ESC Heart Failure 2022 Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients Shelley Wood May 23, 2022
News Conference News EuroPCR 2022 MitraClip ‘Bridge’ Strategy Continues to Help Sickest HF Patients Michael O'Riordan May 20, 2022
News Conference News ACC 2022 METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF Todd Neale April 08, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Daily News In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report Michael O'Riordan January 27, 2022
News Daily News As Amyloidosis Field Explodes, Physicians Need to Spot and Treat Todd Neale October 20, 2021
News Conference News ACC 2021 Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs Todd Neale May 18, 2021
News Conference News ESC 2020 EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF Michael O'Riordan August 28, 2020
News Conference News ACC 2020 A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA Michael O'Riordan March 28, 2020
News Daily News How HF Drugs Help and Harm Female Patients: A Call for Sex-Specific Reporting Shelley Wood February 26, 2019
News Conference News AHA 2018 PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure Michael O'Riordan November 11, 2018